Latham & Watkins Advises GSK in Global Collaboration with Alector

Healthcare and life sciences team advised the science-led global healthcare company in the collaboration.

July 02, 2021

Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.

Latham & Watkins LLP represents GSK in the transaction with a healthcare and life sciences team led by San Diego partner Steve Chinowsky and San Diego counsel Darryl Steensma, with London associate Oliver Mobasser and Bay Area associate Stephanie Blij. Advice was also provided on antitrust matters by Brussels partner David Little, Washington, D.C. counsel Patrick English with London associate Oscar Hayward; on tax matters by Bay Area partner Kirt Switzer, with London associate Aoife McCabe; on regulatory matters by Washington, D.C. partner Ben Haas; and on arbitration matters by New York counsel Santiago Bejarano.

Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.